First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer
In patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events and a significantly ...
Dec 6, 2022
0
3